Courtney Flaherty joined OncLive as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: cflaherty@onclive.com
Immunotherapy and Targeted Therapies Continue to Improve Patient Outcomes in Lung Cancer
March 20th 2023Updated data from key trials in non–small cell lung cancer continue to demonstrate the superiority of immunotherapy and targeted therapy regimens for non–small cell lung cancer treatment, but the optimal use of these agents in the adjuvant vs neoadjuvant settings is still contested.
Read More
Bispecific CD20/CD19-targeted CAR T-cell Therapies May Improve Outcomes in MCL
March 15th 2023Nirav N. Shah, MD, explains the choice to evaluate LV20.19 CAR in MCL, key efficacy and safety data from the follow-up study of this agent, and ongoing efforts to potentially expand its use across other B-cell malignancies.
Read More
Updated MAGNITUDE Data Support Niraparib Combination in mCRPC and HRR Gene Alterations
March 8th 2023Eleni Efstathiou, MD, PhD, expands on the updated interim data from the MAGNITUDE trial and sheds light on the utility of PARP inhibitor combinatorial strategies in patients with mCRPC and HRR gene alterations.
Read More
Enfortumab Vedotin Plus Pembrolizumab May Address Unmet Need in Advanced Urothelial Cancer
March 2nd 2023Jonathan E. Rosenberg, MD, discusses key safety and efficacy data from the EV-103 trial supporting supplemental biologics license applications seeking FDA approval of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer.
Read More
Teclistamab Approval Adds to Bucket of Relapsed/Refractory Multiple Myeloma Options
February 28th 2023Amandeep Godara, MBBS, expands on the advantages and limitations of teclistamab monotherapy in patients with late-relapsed myeloma, discusses the best use of bispecific antibodies and CAR T-cell therapy in this population, and highlights ongoing efforts to mitigate the impact of treatment-related toxicities and improve accessibility across the paradigm.
Read More
Jasmine Sukumar, MD, discusses the purpose of analyzing endocrine therapy use in HR-positive/HER2-positive patients, key data presented from the retrospective analysis at SABCS, and the need for improved understanding of clinical indications for endocrine therapy in this breast cancer subtype.
Read More
Clinical Activity With High-dose HPN217 Warrants Continued Research in R/R Multiple Myeloma
February 20th 2023Al-Ola A. Abdallah, MD, discusses updated safety and efficacy data with HPN217 in relapsed/refractory multiple myeloma and next steps for the investigation as well as sequencing of BCMA-targeted therapies for this patient population.
Read More
Erdafitinib Data in FGFR+ Cholangiocarcinoma Indicates Utility of NGS in Treatment Selection
February 20th 2023Shubham Pant, MD, MBBS, discusses significant efficacy and safety data from the RAGNAR trial, how erdafitinib fits into the current treatment paradigm for biliary tract cancers, and the role of next-generation sequencing in the selection of FGFR inhibitors for this patient population.
Read More
Adjuvant Everolimus Plus Standard ET Does Not Significantly Improve iDFS or OS in HR+ Breast Cancer
February 14th 2023Mariana Chavez-MacGregor, MD, MSC, discussed key efficacy and safety data from the SWOG 1207 trial of adjuvant everolimus in postmenopausal patients with high-risk, hormone receptor–positive breast cancer.
Read More
Checkpoint Inhibitors, FGFR Inhibitors Lead to Continued Advancements in Biliary Tract Cancer
February 13th 2023James Harding, MD, highlighted current and emerging areas of research in biliary tract cancer, including key contributions from TOPAZ-1 and the phase 3 SWOG 1815 trial, the development of immunotherapy and chemotherapy combinations, and continued efforts to utilize personalized medicine in clinical practice.
Read More
Encorafenib/Cetuximab Plus Chemo Viable for Continued Study in BRAF V600E–Mutated mCRC
February 10th 2023Scott Kopetz, MD, discussed the key objectives of the phase 3 BREAKWATER trial being done in patients with BRAF V600E–mutated mCRC, the recently reported safety and efficacy data observed with encorafenib plus cetuximab and chemotherapy, and the importance of conducting biomarker research to further personalize treatment in these patients.
Read More
Zanubrutinib Approval Underscores the Importance of Next-Generation BTK Inhibitors in CLL/SLL
February 7th 2023Lamanna discussed key efficacy and safety data with zanubrutinib from the SEQUOIA and ALPINE trials, the advantages of zanubrutinib compared with previous therapeutic options, and how the approval of the agent will affect the use of next-generation BTK inhibitors in chronic lymphocytic leukemia and small lymphocytic lymphoma .
Read More
Rachna T. Shroff, MD, MS, expands on the rationale for evaluating the addition of nab-paclitaxel to gemcitabine/cisplatin in patients with newly diagnosed biliary tract cancers, data presented from SWOG 1815, and how this study may pave the way for future research efforts in the paradigm.
Read More
Post-Transplant KRd Maintenance May Allow for Superior Outcomes in Newly Diagnosed Multiple Myeloma
February 3rd 2023Andrzej Jakubowiak, MD, PhD, highlighted several key studies that influenced the development and design of the ATLAS trial, introduced conclusions from the initial efficacy data, and discussed how ongoing analysis could further contextualize and inform post-transplant treatment approaches in multiple myeloma.
Read More
Ryan Jacobs, MD, highlighted the updated safety and efficacy results from the minimal residual disease cohort of the CAPTIVATE trial, discussed unanswered questions regarding minimal residual disease as a predictive vs prognostic tool in patients with chronic lymphocytic leukemia, and outlined areas that are ripe for further exploration.
Read More
Nicholas P. McAndrew, MD, MSCE, discusses the need for HER2-targeted TKIs specifically designed to penetrate the blood-brain barrier, updated clinical data on the safety and tolerability of DZD1516 monotherapy, and the implications of nonclinical data on DZD1516 for treating CNS metastases in HER2-positive breast cancer.
Read More
Ibrutinib Plus Chemo Induction Followed by Ibrutinib Maintenance Could Be New Standard in MCL
January 31st 2023Martin Dreyling, MD, discusses the safety and efficacy data from the TRIANGLE study done in patients with previously untreated MCL who are younger than 66 years, and the impact of these results on the use of ASCT in this population.
Read More
Cemiplimab Plus Chemotherapy Expands First-Line Options in Advanced NSCLC
January 30th 2023Ana Baramidze, MD, provides background on the FDA approvals of cemiplimab in NSCLC, expands on key efficacy and safety data with cemiplimab from EMPOWER-Lung 3, and discusses the current treatment landscape for patients with advanced NSCLC.
Read More
Ibrutinib Plus Venetoclax Provides Additional Fixed-Duration Regimen for Elderly Patients With CLL
January 18th 2023Carsten Niemann, MD, PhD, discusses the significance of new data from the GLOW trial, the potential relationship between treatment regimen, minimal residual disease status, and survival outcomes, and the importance of research into precision medicine approaches in chronic lymphocytic leukemia.
Read More
Tucatinib Plus Trastuzumab Could Address Need for New Standard of Care in HER2+ Metastatic CRC
January 18th 2023Tanios S. Bekaii-Saab, MD, FACP, expands on key data reported from the MOUNTAINEER trial, the potential effects of this regimen’s approval on the current treatment landscape, and the continued investigation of this and other targeted approaches in metastatic colorectal cancer.
Read More
Neoadjuvant Anti-HER2 TKIs Require Further Investigation for HER2+ Breast Cancer
January 17th 2023John Crown, MB, BCh, BAO, BSc, MD, MBA, discusses previous research with anti-HER2 TKIs in HER2-positive breast cancer, expanded on key follow-up data from this phase 2 trial, and emphasized the importance of continued investigation into this underutilized combination.
Read More
Genetic Analysis Helps Maximize Clinical Benefit with PARP Inhibitors in BRCA+ Ovarian Cancer
January 17th 2023Saketh Guntupalli, MD, highlights data supporting PARP inhibitors as the standard-of-care frontline therapy, strategies for the management of PARP-related toxicities, and the importance of testing for HRD and BRCA status in patients with ovarian cancer.
Read More
Novel Combination Regimens Strengthen and Expand Treatment Paradigm for Genitourinary Cancers
January 10th 2023Tanya B. Dorff, MD, highlights improvements in the current treatment paradigm for other genitourinary cancers and spotlights efforts being made to expand the role of immunotherapy and targeted therapy combinations.
Read More
BGB-11417 Shows Encouraging Early Efficacy and Tolerability in CLL
January 9th 2023Chan Y. Cheah, MD, MBBS, discusses the the phase 1 BGB-11417-101 trial, which showed that the BCL-2 inhibitor BGB-11417, administered alone or in combination with the BTK inhibitor zanubrutinib, induced promising response rates and was well tolerated patients with chronic lymphocytic leukemia.
Read More
Real-World Analysis Shows Low Use of Ovarian Suppression in Premenopausal HR+/HER2+ Breast Cancer
January 9th 2023Maryam Lustberg, MD, MPH, discusses key results from a retrospective analysis of ovarian suppression in HR–positive, HER2-positive breast cancer, the importance of assessing real-world practice patterns, and the need for continued study of other predictive biomarkers for endocrine therapy in this population.
Read More